Inozyme Pharma, Inc.
INZY
$3.99
$0.0050.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.10% | -25.67% | -47.67% | -73.48% | -34.15% |
| Total Depreciation and Amortization | -3.30% | -15.31% | -6.25% | -10.05% | -12.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,989.29% | 2,559.74% | 252.69% | 32.47% | -101.81% |
| Change in Net Operating Assets | -119.03% | 98.80% | 34.67% | 327.26% | 36.73% |
| Cash from Operations | -18.82% | -3.79% | -30.00% | -52.16% | -38.04% |
| Capital Expenditure | -- | 83.81% | -85.71% | 100.00% | 81.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 223.08% | 342.84% | 152.37% | 209.19% | -25.21% |
| Cash from Investing | 224.07% | 338.64% | 152.33% | 209.12% | -24.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 43.40% | 1,512.50% | -84.91% | -97.16% | 65.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 43.40% | -97.94% | -84.91% | -98.06% | -99.21% |
| Foreign Exchange rate Adjustments | -80.00% | -102.99% | 99.45% | -109.09% | -47.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.11% | 71.61% | 54.41% | 34.50% | -186.72% |